Areteia Therapeutics announces the appointment of Christopher Courts, CPA as Chief Financial Officer
Areteia Therapeutics announces the appointment of Christopher Courts, CPA as Chief Financial Officer. Christopher will report to Jorge Bartolome, CEO of Areteia Therapeutics, effective immediately.
Christopher is a seasoned industry executive with over 20 years of experience in public and private life science companies. Most recently, Christopher served as Chief Financial Officer at Pebble Labs, a biotech company creating safe and effective biological solutions to sustainably protect yields and quality in food production, where he led financial operations, strategic planning, and business development.
Prior to Pebble Labs, Christopher served as CFO and founding member of Regado Biosciences’ executive team. He was responsible for the company’s finance and accounting functions, as well as raising $260M in private and public equity financings. Christopher managed the S1 process culminating with the company’s successful IPO.
“I am delighted to be welcoming another experienced member to the executive team at Areteia Therapeutics,” said Jorge Bartolome, CEO of Areteia Therapeutics. He added “Chris will play an essential role in fulfilling our company’s mission to put asthma patients in better control of their disease and lives.”
About Areteia Therapeutics
Areteia Therapeutics (areteiatx.com) is a clinical stage biotechnology company committed to putting asthma patients in better control of their disease and lives by developing the first potential oral drug for eosinophilic asthma. Areteia’s lead drug candidate is dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences. A syndicate of leading life sciences and strategic investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners, has committed to invest up to $350 million in Series A financing to establish Areteia and advance dexpramipexole through Phase 3 clinical trials, secure commercial supply, and pursue potential next-generation medicines. Areteia will conduct late-stage development including Phase 3 clinical trials of dexpramipexole in partnership with Population Health Partners’ development unit, Validae Health.
About Dexpramipexole
Dexpramipexole is an oral small molecule in phase 3 development for eosinophilic asthma. Dexpramipexole inhibits the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels. Most recently in a Phase 2 study in patients with moderate-to-severe eosinophilic asthma, treatment with dexpramipexole resulted in a significant, dose-dependent reduction in blood absolute eosinophil count at all doses tested (daily dexpramipexole doses of 37.5 mg, 75 mg, or 150 mg twice daily) compared to placebo. Dexpramipexole was well tolerated in the trial, with adverse events balanced across treatment and placebo groups, no serious adverse events, and no adverse events leading to discontinuation.
About Eosinophilic Asthma
Asthma disrupts the lives of more than a quarter of a billion people worldwide. More than half of asthma patients have eosinophilic asthma, which is driven by an oversupply of eosinophils, a type of white blood cell, in blood and tissue. By inhibiting the maturation of eosinophils, oral dexpramipexole acts in a way similar to injectable anti-IL-5 biologic therapies. The asthma biologic market is experiencing growth of 10% per year and is valued at around $8 billion, with IL-5 biologic therapies representing approximately $3 billion of that figure. If approved as a first-to-market oral, dexpramipexole could provide a compelling alternative to injectable biologics, and could potentially be used earlier in the asthma treatment paradigm to prevent progression of disease.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005055/en/
Contact information
Tamsin Berry
Tamsin.Berry@areteiatx.com
Mark Kreston
Mark.Kreston@areteiatx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thredd Enters the Credit Space Partnering with LoanPro to Power Next-Generation Credit Capabilities27.10.2025 23:00:00 EET | Press release
Thredd, the leading next-generation global payments processor, today announced its selection of LoanPro, the modern credit platform, to underpin Thredd’s new suite of credit solutions for fintechs and financial organizations. The partnership marks a significant milestone in Thredd’s strategy to deliver full-stack embedded issuing and processing capabilities inclusive of credit, debit and prepaid. By integrating LoanPro’s advanced, composable credit infrastructure with Thredd’s next gen real-time card issuance and processing capabilities, including digital wallets and embedded fraud detection, clients will be able to design, launch and scale differentiated credit products with unprecedented speed and personalization. The collaboration leverages LoanPro’s category-leading expertise in powering innovative credit programs for leading financial organizations, while reinforcing Thredd’s position as a platform-first global player. “Credit-based value propositions drive not only more opportuni
CMA Approves Amendments to Investment Accounts Instructions to Strengthen Foreign Investor Access and Enhance Market Efficiency27.10.2025 19:29:00 EET | Press release
The Capital Market Authority (CMA) of Saudi Arabia has approved a set of amendments to the regulatory framework governing the procedures for opening and operating investment accounts. These changes aim to facilitate access for a broader base of foreign investors and align with the Kingdom's regulatory and technological developments. The amendments are part of CMA’s ongoing efforts to enhance the investment environment and expand the investor base in the Saudi capital market. The requirements for opening an investment account for individual foreign investors residing in one of the GCC countries have been developed. In addition, the scope of securities that they can directly invest in now includes the shares of listed companies on the Saudi Main Market (TASI). Before these facilitations, their access was limited to the debt instruments market, the Parallel Market (Nomu), investment funds, and the derivatives market. Furthermore, trading in the main market was previously restricted to bei
Carbon Measures and International Chamber of Commerce Launch Technical Expert Panel on Carbon Accounting27.10.2025 18:11:00 EET | Press release
Carbon Measures and the International Chamber of Commerce (ICC) today announced the formation of an independent expert panel that will work to develop the guidelines and implementation steps to establish a global carbon emissions accounting system based on financial accounting principles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027348594/en/ The Technical Expert Panel on Carbon Accounting will be comprised of experts from academia, financial accounting, industry and civil society, representing multiple perspectives and geographies. Together, they will define the principles, scope, and applications of a carbon emissions accounting system modeled on financial accounting principles. Such a system would provide accurate, transparent, verifiable, and timely company- and product-level data, ensuring every tonne of carbon emissions is counted only once and attributed correctly at each step of the value chain. The panel wi
IAMPHENOM Europe Expands All-Star Speaker Lineup27.10.2025 15:30:00 EET | Press release
Phenom, an applied AI company that helps organisations hire faster, develop better and retain longer, announced a second wave of confirmed speakers joining its inaugural IAMPHENOM Europe conference — the only applied AI event for human resources. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027606156/en/ Phenom announced a second wave of confirmed speakers joining its inaugural IAMPHENOM Europe conference — the only applied AI event for human resources. Featuring visionary keynotes, customer-led breakout sessions, live demonstrations of use-case specific AI agents, and networking opportunities across HR and IT, the in-person event will take place 6 November in Munich. Session topics will include how to: assess AI and automation maturity levels; deploy 25+ AI agents; uphold compliance while navigating European regulations; develop and retain internal talent while attracting external skills; drive unprecedented recruiter
ThetaRay and Kaufman Rossin Announce AI AML Model Validation at Money20/20 USA27.10.2025 15:00:00 EET | Press release
ThetaRay, a global leader in Cognitive AI financial crime compliance, today announced that Kaufman Rossinhas completed an independent validation of its AML Transaction Monitoring and OFAC Screening Modules. Finalized in August 2025, the review confirms that ThetaRay’s AI models demonstrate the governance, transparency, and robustness regulators increasingly expect from AI-driven compliance systems. The announcement will be featured at Money20/20 USA, where the future of finance and compliance technology takes center stage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027724792/en/ A timely milestone in a shifting regulatory landscape In the United States, regulators are sharpening their focus on model risk management. FinCEN’s proposed modernization of the Bank Secrecy Act emphasizes dynamic, risk-based compliance programs and heightened oversight of third-party models. In the European Union, the newly enacted AI Act se
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom